Ipsen: drug approved in thyroid cancer
(CercleFinance.com) - Ipsen announces that the European Commission has approved the use of Cabometyx (cabozantinib) as a second-line treatment for radioactive iodine refractory differentiated thyroid cancer.
The pharmaceutical group said that this approval is the first of its kind in Europe for this rare disease. Treatment options are currently limited if the disease progresses after systemic therapy.
The Brussels approval is based on the results of the pivotal phase III COSMIC-311 study, in which the primary endpoint of progression-free survival (PFS) was met in a planned interim analysis.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
The pharmaceutical group said that this approval is the first of its kind in Europe for this rare disease. Treatment options are currently limited if the disease progresses after systemic therapy.
The Brussels approval is based on the results of the pivotal phase III COSMIC-311 study, in which the primary endpoint of progression-free survival (PFS) was met in a planned interim analysis.
Copyright (c) 2022 CercleFinance.com. All rights reserved.